Previous 10 | Next 10 |
The #priceactio n in Hologic (NASDAQ: HOLX) can help investors find #opportunity and integrate #riskmanagement tools . Stock Traders Daily has demonstrated that in this article. Review The plans for HOLX below, and you will see how this works. Keep in mind, this ...
Thermo Fisher Scientific is a good-quality stock that is well-positioned to grow via M&A and organically in a growing industry. We outline the recent PPD, Inc. acquisition. We perform a DCF valuation to determine Thermo Fisher's fair value. For further details see: T...
In April, I continued to use a strategy of holding income funds and swing trading under-performing S&P 500 stocks to realize profits. I closed 3 stock trades in April for a net cost-weighted gain, including dividends, of 32.96%. The cumulative cost-weighted gain for 41 trades to d...
Image source: The Motley Fool. Hologic Inc (NASDAQ: HOLX) Q2 2021 Earnings Call Apr 28, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Hologic Inc (HOLX) Q2 2021 Earnings Call Transcript
Hologic, Inc. (HOLX) Q2 2021 Results Conference Call April 28, 2021 04:30 PM ET Company Participants Michael Watts - Vice President of Investor Relations and Corporate Communications Stephen MacMillan - President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference...
Hologic (HOLX) has lost ~6.8% in the post-market after the company’s Q2 earnings for fiscal 2021 failed to meet the consensus. Revenue was in line after recording a ~103.4% YoY growth to reach $1.5B. It is an acceleration from ~89.3% posted in Q1 FY21.Diagnosti...
Hologic (HOLX): FQ2 Non-GAAP EPS of $2.59 misses by $0.03; GAAP EPS of $2.38 misses by $0.06.Revenue of $1.54B (+103.7% Y/Y) in-line.Organic Revenue Increases 104.7%, 100.0% in Constant CurrencyFQ3 2021 Guidance: Revenue: Revenue: $1,000 - $1,070M versus consensus of $1.29B; EPS:...
-- Revenue of $1.538 Billion Increases 103.4%, 98.7% in Constant Currency -- -- Organic Revenue Increases 104.7%, 100.0% in Constant Currency -- -- Company Posts GAAP Diluted EPS of $2.38, Non-GAAP Diluted EPS of $2.59 -- Hologic, Inc. (Nasdaq: HOLX) announced today the ...
Influential #investors can create defining moments in a stock's price, by simply making large #buyandsell decisions, and Hologic (NASDAQ: HOLX) is no exception. Pivot points in a chart pattern are often created by these events, and as we have learned this does not require inst...
Abbott Laboratories ([[ABT]] +0.3%) managed to beat the Street forecasts for Q1 2021 earnings but its revenue failed to do the same as its COVID-19 testing-related sales witnessed a ~8.3% decline sequentially from $2.4B in Q4 2020.The reported revenue from the diagnostic segment which in...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...